Bio-Rad Laboratories, Inc. Class A Common Stock vs Riot Platforms Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.42 (market cap $9.43B), while Riot Platforms Inc trades at $20.89 (market cap $7.59B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| BIO | RIOT | |
|---|---|---|
Market Cap | $9.43B | $7.59B |
Sector | Health | Technology |
52-Week High | $356.25 | $28.67 |
52-Week Low | $241.71 | $11.33 |
Enterprise Value | $9.18B | $8.00B |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
RIOT Platforms trades at $20.90, up 7.73% in the last 24 hours, following the announcement of a landmark $9.1 billion, 20-year AI data center deal with Anthropic. Despite this positive news, the technical outlook remains bearish, and the company continues to report significant net losses, with a net income margin of -196.28% for 2026. Analyst sentiment is overwhelmingly positive, with a consensus price target of $33.40 representing substantial upside potential.
The stock presents a high-risk, high-reward opportunity. The transformative AI deal offers a clear long-term growth catalyst, but investors must weigh this against persistent unprofitability and negative cash flows. The key risk is the company's ability to execute its strategic pivot to AI infrastructure while managing its financial losses.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →